John R. Eckardt
Impact in
Papers in
- Oncology 49
- Lung Cancer Research Studies 37
- Neutropenia and Cancer Infections 12
- Cancer Treatment and Pharmacology 10
-
- Cancer therapeutics and mechanisms 35
- Co-authors
- Howard A. Burris (20 shared papers)Daniel D. Von Hoff (30 shared papers)Geoffrey R. Weiss (19 shared papers)John G. Kuhn (14 shared papers)Susan G. Hilsenbeck (6 shared papers)G I Rodriguez (9 shared papers)Mace L. Rothenberg (8 shared papers)Lon Smith (8 shared papers)
- Journals
- Journal of Clinical Oncology (26 papers)Lung Cancer (9 papers)Blood (6 papers)Annals of Oncology (5 papers)Investigational New Drugs (3 papers)
- Partner nations
- United StatesFranceUnited Kingdom
In The Last Decade
John R. Eckardt
83 papers receiving 3.1k citations
Peers
Comparison fields: 5 of 107
- Oncology 1.7k
- Genetics 265
- Hematology 212
- Molecular Biology 1.3k
- Toxicology 64
Countries citing papers authored by John R. Eckardt
This map shows the geographic impact of John R. Eckardt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John R. Eckardt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John R. Eckardt more than expected).
Fields of papers citing papers by John R. Eckardt
This network shows the impact of papers produced by John R. Eckardt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John R. Eckardt. The network helps show where John R. Eckardt may publish in the future.
Co-authors
The 25 scholars most cited alongside John R. Eckardt, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 85 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 1996 | 306 | |
| 2 | 2007 | 277 | |
| 3 | 1993 | 262 | |
| 4 | 1995 | 132 | |
| 5 | 1993 | 120 | |
| 6 | 1999 | 118 | |
| 7 | 2006 | 111 | |
| 8 | 1994 | 99 | |
| 9 | 2009 | 79 | |
| 10 | 1998 | 74 | |
| 11 | 1995 | 73 | |
| 12 | 1998 | 67 | |
| 13 | 1997 | 66 | |
| 14 | 2002 | 63 | |
| 15 | A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. | 1999 | 63 |
| 16 | 1999 | 62 | |
| 17 | 1999 | 57 | |
| 18 | 2011 | 53 | |
| 19 | A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin) | 1999 | 53 |
| 20 | Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study. | 1997 | 49 |
About John R. Eckardt
John R. Eckardt is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Epidemiology and Genetics, having authored 85 papers that have together received 3.2k indexed citations. Recurring topics across this work include Lung Cancer Research Studies (37 papers), Cancer therapeutics and mechanisms (35 papers), Neuroendocrine Tumor Research Advances (17 papers), Lung Cancer Treatments and Mutations (14 papers), Neutropenia and Cancer Infections (12 papers), Cancer Treatment and Pharmacology (10 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Acute Myeloid Leukemia Research (5 papers). The work is most often cited by research in Oncology (1.7k citations), Genetics (265 citations), Hematology (212 citations), Molecular Biology (1.3k citations) and Toxicology (64 citations). John R. Eckardt has collaborated with scholars based in United States, France and United Kingdom. Frequent co-authors include Howard A. Burris, Daniel D. Von Hoff, Geoffrey R. Weiss, John G. Kuhn, Susan G. Hilsenbeck, G I Rodriguez, Mace L. Rothenberg, Lon Smith, David Rinaldi and S. Gail Eckhardt. Their work appears in journals such as Journal of Clinical Oncology, Lung Cancer, Blood, Annals of Oncology and Investigational New Drugs.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.